Skip to main content

Advertisement

Log in

Anorectic Drugs: Use in General Practice

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The treatment of obesity is one of the major measures available today in the field of preventive medicine. In particular, the coronary epidemic of Western civilisation would be halted, and most cases of maturity-onset diabetes prevented, if obesity were to be treated effectively.

Anorectic drugs act mainly on the satiety centre in the hypothalamus to produce anorexia. They also have various metabolic effects involving fat and carbohydrate metabolism, but many of these may be secondary to loss of weight. Most of the drugs are related directly or indirectly to amphetamine and in addition act by increasing general physical activity. Anorectic drugs tend to lose their effect after some months, and part of this reduction in effect may be due to chemical alterations produced by the drugs in the brain. All the drugs, with the exception of fenfluramine, have a stimulant effect on the central nervous system in some individuals, resulting in restlessness and nervousness, irritability and insomnia. Fenfluramine commonly produces drowsiness in normal doses, but has stimulant effects with overdosage. Dexamphetamine, phenmetrazine and benzphetamine all tend to cause euphoria and the risk of addiction is therefore considerable. Euphoria occasionally occurs with diethylpropion, phentermine and chlorphentermine, but to a much lesser extent.

Side-effects also occur due to sympathetic stimulation and gastro-intestinal irritation. These side-effects may cause some individuals to stop taking the drug, but are never serious or dangerous. Drug interactions may occur with monoamine oxidase inhibitors and to a clinically unimportant extent, with antihypertensive drugs.

The anorectic drugs have a very definite part to play in the treatment of obesity, mainly for those individuals who have altered their eating habits but have come to a plateau of weight which they find difficult to get below. The drugs are best given in a long-acting form and can safely be continued as long as weight loss persists, provided that the clinician exercises careful supervision. Dexamphetamine, phenmetrazine and benzphetamine should rarely be used because of the danger of addiction, and chlorphentermine is potentially hazardous for long-term use. Diethylpropion emerges as the drug of first choice, as fenfluramine has a tendency to cause depression and has a higher incidence of side-effects. Fenfluramine is mainly useful for people who are especially tense and for obese maturity-onset diabetics who have been unable to lose weight with the biguanides. Mazindol and phentermine appear to be useful as alternative drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Anand, B.K.: Effect of fenfluramine on activity of feeding satiety centres of hypothalamus. South African Medical Journal 19 (Suppl. 19th June): 12 (1971).

    Google Scholar 

  • Bethel, M.F.: Toxic psychosis caused by ‘Preludin’. British Medical Journal 1: 30 (1957).

    Article  Google Scholar 

  • Brandon, S.: Unusual effect of fenfluramine. British Medical Journal 2: 557 (1969).

    Article  Google Scholar 

  • Butterfield, W.J.H. and Wichelow, M.F.: Fenfluramine and muscle glucose uptake in man. Lancet 2: 109 (1968a).

    Article  Google Scholar 

  • Butterfield, W.J.H. and Wichelow, M.F.: Effect of diet, sulphonylureas and phenformin on peripheral glucose uptake in diabetics and obese. Lancet 2: 785 (1968b).

    Article  PubMed  CAS  Google Scholar 

  • Campbell, D.B.: Plasma concentration of fenfluramine and its metabolite norfenfluramine following single and repeated oral administration. British Journal of Pharmacology 43: 465 (1971).

    Google Scholar 

  • Campbell, D.B.: and Moore, B.R.W.: Fenfluramine over-dosage. Lancet 2: 1307 (1969).

    PubMed  CAS  Google Scholar 

  • Craddock, D.: Obesity and its management, 2nd Ed., p.16 and 126 (Churchill Livingstone, Edinburgh and London 1973).

    Google Scholar 

  • Darmady, J.M.: Diazepam for fenfluramine intoxication. Archives of Disease in Childhood 49: 328 (1974).

    Article  PubMed  CAS  Google Scholar 

  • De Felice, E.A.; Bronstein, S. and Cohen, A.: Double-blind comparison of placebo and 42-548, a new appetite suppressant, in obese volunteers. Current Therapeutic Research 11: 256 (1969).

    PubMed  Google Scholar 

  • De Felice, E.A.; Chaykin, L.B. and Cohen, A.: Double-blind clinical evaluation of mazindol, dextroamphetamine and placebo in treatment of exogenous obesity. Current Therapeutic Research 15: 358 (1973).

    Google Scholar 

  • Dykes, J.R.W.: The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics. Postgraduate Medical Journal 49: 318 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Evans, J.: Psychosis and addiction to phenmetrazine. Lancet 2: 152 (1959).

    Article  PubMed  CAS  Google Scholar 

  • Fleisher, M.R. and Campbell, D.B.: Fenfluramine over-dosage. Lancet 2: 1306 (1969).

    PubMed  CAS  Google Scholar 

  • Follows, O.J.: A comparative trial of fenfluramine and diethylpropion in obese hypertensive patients. British Journal of Clinical Practice 25: 236 (1971).

    PubMed  CAS  Google Scholar 

  • Gaind, R.: Psychological aspects of the aetiology and treatment of obesity. South African Medical Journal 19 (Suppl. 19th June): 36 (1971).

    Google Scholar 

  • Garrow, J.S.; Belton, E.A. and Daniel, A.: A controlled investigation of the ‘glycolyptic’ action of fenfluramine. Lancet 2: 559 (1972).

    Article  PubMed  CAS  Google Scholar 

  • General Practitioner Research Group: Hypotensive effect of fenfluramine in the treatment of obesity. Practitioner 207: 101 (1971).

    Google Scholar 

  • Goldrick, R.B.; Nestel, P.J. and Havenstein, N.: Comparison of a new anorectic agent AN 448 with fenfluramine in the treatment of refractory obesity. Medical Journal of Australia 1: 882 (1974).

    PubMed  CAS  Google Scholar 

  • Gotestam, K.G. and Gunne, L.N.: Subjective effects of two anorexigenic agents, fenfluramine and AN 448, in amphetamine dependent subjects. British Journal of Addiction 67: 39 (1972).

    Article  CAS  Google Scholar 

  • Griffith, J.D.; Witt, J.G. and Jasinski, D.R.: A comparison of fenfluramine and d-amphetamine in man. Clinical Pharmacology and Therapeutics 15: 207 (1974).

    Google Scholar 

  • Hadler, A.J.: Mazindol, a new non-amphetamine anorexigenic agent. Journal of Clinical Pharmacology 12: 453 (1972).

    CAS  Google Scholar 

  • Heath, D.A.: Heart failure in a middle-aged woman. British Medical Journal 4: 777 (1972).

    Article  Google Scholar 

  • Hill, R.C. and Turner, P.: Fenfluramine and critical flicker frequency. Journal of Pharmacy and Pharmacology 19: 337 (1967).

    Article  PubMed  CAS  Google Scholar 

  • Hedges, A.: AN 448 on critical flicker frequency and heart rate in man. South African Medical Journal 46: 139 (1972).

    PubMed  CAS  Google Scholar 

  • Hodges, R.E. and Krehl, W.A.: The role of carbohydrates in lipid metabolism. American Journal of Clinical Nutrition 17: 334 (1965).

    PubMed  CAS  Google Scholar 

  • Imlah, N.W.: Unusual effect of fenfluramine. British Medical Journal 2: 178 (1970).

    Article  PubMed  CAS  Google Scholar 

  • Jones, H.S.: Fenfluramine used as a substitute for methylamphetamines and dexamphetamines in the treatment of dependence on these drugs. South African Medical Journal 19 (Suppl. 19th June): 31 (1971).

    Google Scholar 

  • Kannel, W.B. and Gordon, T.: in Burland, Samuel and Yudkin (Eds) Obesity, p.24 (Churchill Livingstone, Edinburgh, London and New York 1974).

  • Le Riche, W.H. and Csima, A.: A long-acting appetite suppressant drug studied for 24 weeks in both continuous and sequential administration. Canadian Medical Association Journal 97: 1016 (1967).

    PubMed  Google Scholar 

  • Levin, A.: Abuse of fenfluramine. British Medical Journal 2: 49 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Lewis, S.A.; Oswalk, I. and Dunleavy, D.I.F.: Chronic fenfluramine administration: Some cerebral effects. British Medical Journal 2: 624 (1971).

    Article  Google Scholar 

  • Lüllmann-Rauch, R. and Reil, G-H.: Chlorphentermine-induced lipidosis like ultrastructural alterations in lungs and adrenal glands of several species. Toxicology and Applied Pharmacology 30: 408 (1974).

    Article  PubMed  Google Scholar 

  • Mace, P.M.; Malcolm, A.D.; Outar, K.P. and Pawan, G.L.S.: Comparative effects of four anti-obesity agents on blood plasma lipids in man. Proceedings of the Nutrition Society 31: 12A (1972).

    PubMed  Google Scholar 

  • McKay, R.H.G.: Long-term use of diethylpropion in obesity. Current Medical Research and Opinion 1: 489 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Malcolm, A.D.; Mace, P.M.; Outar, K.P. and Pawan, G.L.S.: Experimental evaluation of anorexigenic agents in man: A pilot study. Proceedings of the Nutrition Society 31: 12A (1972).

    PubMed  CAS  Google Scholar 

  • Munro, J.F.; MacCuish, A.C.; Wilson, E.M. and Duncan, L.J.P.: Comparison of continuous and intermittent anorectic therapy in obesity. British Medical Journal 1: 352 (1968).

    Article  PubMed  CAS  Google Scholar 

  • Murphy, J.E.; Donald, J.F.; Molla, A.L. and Crowder, D.: A comparison of mazindol (‘Teronac’) with diethylpropion in the treatment of exogenous obesity. Journal of International Medical Research 3: 202 (1975).

    PubMed  CAS  Google Scholar 

  • Oswald, I.; Jones, H.S. and Mannerhein, J.E.: Effects of two slimming drugs on sleep. British Medical Journal 1: 796 (1968).

    Article  PubMed  CAS  Google Scholar 

  • Oswald, I.; Lewis, S.A.; Dunleavy, D.L.F.; Brezinova, B. and Briggs, M.: Drugs of dependence though not of abuse; fenfluramine and imipramine. British Medical Journal 3: 70 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Pawan, G.: Effect of fenfluramine on blood lipids in man. Lancet 1: 498 (1969).

    Article  PubMed  CAS  Google Scholar 

  • Pawan, G.: A comparative study of effects of fenfluramine and diethylpropion on food uptake, body composition, blood lipids and O2 uptake in mice. South African Medical Journal 19 (Suppl. 19th June): 14 (1971).

    Google Scholar 

  • Quaade, F. and Judhl, O.: On the ‘glucostatic’ theory of appetite regulation. American Journal of Medical Science 243: 438 (1962).

    Article  CAS  Google Scholar 

  • Royal Australasian College of Physicians: Report on anorectic drugs and central nervous stimulants. Australian Government Publishing Service (Canberra, 1974).

  • Seedat, Y.K. and Reddy, J.: Diethylpropion hydrochloride (‘Tenuate Dospan’) in combination with hypotensive agents in the treatment of obesity associated with hypertension. Current Therapeutic Research 16: 398 (1974).

    PubMed  CAS  Google Scholar 

  • Silverstone, T.: Intermittent treatment with anorectic drugs. Practitioner 213: 245 (1974).

    PubMed  CAS  Google Scholar 

  • Silverstone, J.T.; Cooper, R.M. and Begg, R.R.: A comparative trial of fenfluramine and diethylpropion in obesity. British Journal of Clinical Practice 24: 423 (1970).

    PubMed  CAS  Google Scholar 

  • Silverstone, T. and Cleary, T.: The treatment of obesity: A controlled trial of an evening dose of Tenuate (diethylpropion). Clinical Trials Journal 4: 837 (1967).

    Google Scholar 

  • Silverstone, T. and Turner, P.: in Drug Treatment in Psychiatry, p.94 (Routledge and Keagan Paul, London 1974).

    Google Scholar 

  • Sirtori, C.; Hurtwitz, A. and Azarnoff, D.L.: Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine. American Journal of Medical Science 261: 341 (1971).

    Article  CAS  Google Scholar 

  • Steel, J.M. and Briggs, M.: Withdrawal depression in obese patients after fenfluramine treatment. British Medical Journal 3: 26 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Steel, J.M.; Munro, J.F. and Duncan, L.J.P.: A comparative trial of different regimens of fenfluramine and phentermine in obesity. Practitioner 211: 232 (1973).

    PubMed  CAS  Google Scholar 

  • Stunkard, A.; Rickeis, K. and Hesbacher, P.: Fenfluramine in the treatment of obesity. Lancet 1: 503 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Testa, B. and Beckett, A.H.: Metabolism and excretion of diethylpropion in man under acidic urine conditions. Journal of Pharmacy and Pharmacology 25: 199 (1973).

    Article  Google Scholar 

  • Turtle, J.R. and Burgess, J.A.: Hypoglycaemic action of fenfluramine in diabetes mellitus. Diabetes 22: 858 (1973).

    PubMed  CAS  Google Scholar 

  • Van Rooyen, R.J. and Van der Merwe, M.: Comparison of diethylpropion (‘Tenuate Dospan’) and fenfluramine. Medical Proceedings 17: 420 (1971).

    Google Scholar 

  • Vernace, B.J.: Controlled comparative investigation of mazindol, d-amphetamine and placebo. Obesity/ Bariatric Medicine 3: 124–129 (1974).

    Google Scholar 

  • Walsh, A.L.: in Side Effects of Anti-Obesity Drugs (Thomas Springfield 1962).

  • Waal-Manning, H.J. and Simpson, F.E.: Fenfluramine in obese patients on various antihypertensive drugs. Lancet 4: 1392 (1969).

    Article  Google Scholar 

  • Wilson, J.P.D. and Galton, D.J.: The effect of drugs on lipogenesis from glucose and palmitate in human adipose tissue. Hormone and Metabolic Research 3: 262 (1971).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Craddock, D. Anorectic Drugs: Use in General Practice. Drugs 11, 378–393 (1976). https://doi.org/10.2165/00003495-197611050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-197611050-00002

Keywords

Navigation